Download Files:
Vipivotide tetraxetan
$350 – $4,350
Products Details
Product Description
– Vipivotide tetraxetan (PSMA-617) is a high potent prostate-specific membrane antigen (PSMA) inhibitor, with a Ki of 0.37 nM. Vipivotide tetraxetan (PSMA-617) is designed consisting of three components: the pharmacophore Glutamate-urea-Lysine, the chelator DOTA able to complex both 68Ga or 177Lu, and a linker connecting these two entities. Glutamate-urea-Lysine is the selective pharmacophore to bind to prostate specific membrane antigen.
Web ID
– HY-117410
Storage Temperature
– -20°C, 3 years; 4°C, 2 years (Powder)
Shipping
– Room Temperature
Applications
– Cancer-programmed cell death
Molecular Formula
– C49H71N9O16
References
– [1]BeneÅ¡ová M, et al. Preclinical Evaluation of a Tailor-Made DOTA-Conjugated PSMA Inhibitor with Optimized Linker Moiety for Imaging and Endoradiotherapy of Prostate Cancer. J Nucl Med. 2015 Jun;56(6):914-20.
CAS Number
– 1702967-37-0
Molecular Weight
– 1042.14
Compound Purity
– 99.57
SMILES
– O=C(O)[C@H](CCCCNC([C@H](CC1=CC=C2C=CC=CC2=C1)NC([C@H]3CC[C@H](CNC(CN4CCN(CC(O)=O)CCN(CC(O)=O)CCN(CC(O)=O)CC4)=O)CC3)=O)=O)NC(N[C@H](C(O)=O)CCC(O)=O)=O
Clinical Information
– Phase 2
Research Area
– Cancer
Solubility
– DMSO : 125 mg/mL (ultrasonic)|H2O : ≥ 100 mg/mL
Target
– Drug-Linker Conjugates for ADC
Isoform
– Traditional Cytotoxic Agents
Pathway
– Antibody-drug Conjugate/ADC Related
Product type
– ADC Related
Disclaimer: All products are for research use only unless clearly stated otherwise on the product datasheet. Datasheets provided on the website are drafts for reference purpose only and you are requested to always refer to the hard copy included in the kit for your experimentation.
